The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

Haixia Qin; Manish R. Patel

doi:10.3390/ijms23062916

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

Haixia Qin, Manish R. Patel

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.

Original language	English (US)
Article number	2916
Journal	International journal of molecular sciences
Volume	23
Issue number	6
DOIs	https://doi.org/10.3390/ijms23062916
State	Published - Mar 1 2022

Bibliographical note

Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Drug resistance
NTRK
Non-small cell lung cancer

PubMed: MeSH publication types

Journal Article
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3390/ijms23062916

OpenUrl availability

Full text

Cite this

@article{0707c7971ca3461cacd18466c1fd7bc1,

title = "The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer",

abstract = "With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.",

keywords = "Drug resistance, NTRK, Non-small cell lung cancer",

author = "Haixia Qin and Patel, {Manish R.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = mar,

day = "1",

doi = "10.3390/ijms23062916",

language = "English (US)",

volume = "23",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "6",

}

TY - JOUR

T1 - The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

AU - Qin, Haixia

AU - Patel, Manish R.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.

AB - With the development of targeted therapy, non-small cell lung cancer (NSCLC) patients could have more treatment choices if target mutation presents. The neurotrophic tropomyosin receptor kinase (NTRK) has a low prevalence in NSCLC, roughly around 0.5%. FDA had approved two first generation NTRK inhibitors, larotrectinib and entrectinib. Both medications have excellent CNS penetration. This manuscript will review available data on targeting NTRK fusions in NSCLC and mechanisms of drug resistance.

KW - Drug resistance

KW - NTRK

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=85126065060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126065060&partnerID=8YFLogxK

U2 - 10.3390/ijms23062916

DO - 10.3390/ijms23062916

M3 - Review article

C2 - 35328336

AN - SCOPUS:85126065060

SN - 1661-6596

VL - 23

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 6

M1 - 2916

ER -

The Challenge and Opportunity of NTRK Inhibitors in Non-Small Cell Lung Cancer

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this